T-cell receptor recognizing melanoma peptide–MHC complex (TCR-pMHC) (TCR-pMHC (Melanoma))

T-cell receptors (TCRs) recognizing melanoma peptide–MHC complexes are specialized proteins that enable the immune system to detect intracellular melanoma antigens presented on the cell surface (PubMed: 30103341). These receptors bind to specific peptides derived from proteins like gp100, MART-1, or NY-ESO-1 when they are displayed by Major Histocompatibility Complex (MHC) molecules, most commonly HLA-A*02:01 (NIH: PMC6513117). In clinical oncology, these TCRs serve as the foundation for TCR-engineered T-cell (TCR-T) therapies and bispecific T-cell engagers like Tebentafusp, which is FDA-approved for uveal melanoma (FDA: Kimmtrak Label). The biological function of these receptors is to initiate a signaling cascade that leads to T-cell proliferation and the release of cytotoxic granules to destroy the target cell. While highly effective, these therapies can cause 'on-target, off-tumor' toxicities if the target antigen is also expressed in healthy tissues, such as melanocytes in the skin or eye (PubMed: 22394914). Consequently, patient selection relies heavily on HLA typing and confirmed tumor antigen expression to ensure safety and efficacy. These receptors are distinct from Chimeric Antigen Receptors (CARs) because they can recognize intracellular proteins processed into peptides, significantly expanding the range of targetable melanoma antigens.

Other names

Melanoma-specific T-cell receptorMART-1-specific TCRgp100-specific TCRNY-ESO-1-specific TCRMelanoma antigen-recognizing T-cell receptorMAGE-A3/A4-specific TCR

Engineered T-cells (TCR-T) or soluble bispecific TCR molecules utilize these receptors to specifically recognize and bind melanoma-associated peptides presented by MHC molecules, facilitating the formation of an immunological synapse and subsequent T-cell mediated lysis of the tumor cells.